What Partamol-Codein Treats: Main Uses and Benefits

The combination of ingredients in Partamol-Codein is used when symptoms related to physical discomfort are more noticeable, where supportive symptom management beyond standard over-the-counter options is needed. This medication is generally used to provide symptomatic relief for pain. It is commonly used to help manage symptoms associated with moderate to severe acute pain, including those linked to post-operative recovery, dental procedures, and pain following traumatic injuries.

The medication helps address symptom clusters that may become intense or disruptive in situations where additional symptomatic support is needed. “The goal is to provide supportive relief when symptoms interfere with routine activities.” This approach supports the patient during difficult episodes by easing distress and assists with maintaining functional stability during symptomatic periods. Beyond pain management, the combination is also relevant in conditions presenting with systemic discomfort, as it is commonly used to help with symptomatic relief for fever and pain.

---

Quick Fact: Relief for Moderate to Severe Acute Pain

Category	Description
Main Use	Symptomatic relief of acute pain when standard non-opioids are inadequate.
Key Scenarios	Post-operative discomfort, acute dental pain, post-traumatic pain.
Dual Benefit	Pain management and supportive reduction of associated fever.

Regulatory References

1. MedlinePlus Drug Information

Partamol-Codein (Acetaminophen/Codeine) eligibility is strictly defined by government regulatory agencies based on the risk of respiratory depression and toxicity. The following populations are addressed in official drug labels:

---

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is contraindicated:	Individuals with hypersensitivity to codeine or acetaminophen; all children younger than 12 years; CYP2D6 ultra-rapid metabolizers; patients with severe respiratory depression or severe hepatic impairment; and breastfeeding women.
Age-related eligibility rules:	Contraindicated in children under 12 years for all indications. Contraindicated in children/adolescents under 18 years following tonsillectomy or adenoidectomy due to increased risk of breathing issues.
Condition-specific eligibility rules:	Use is restricted or requires caution in patients with pre-existing conditions like significant respiratory depression, head injury, or impaired renal/hepatic function. Use is not recommended for adolescents aged 12-18 with compromised respiratory function.
Pregnancy and lactation eligibility status:	Contraindicated during breastfeeding. Use in the third trimester of pregnancy is associated with a risk of Neonatal Opioid Withdrawal Syndrome (NOWS).

---

Connection to the overall eligibility profile

Official regulatory documents define non-eligibility through a mandatory list of contraindications. The strictest prohibitions apply to pediatric groups and individuals with a heightened genetic risk (ultra-rapid metabolizers) or physiological risk (breastfeeding women), prioritizing protection against fatal respiratory depression. All other eligible use is conditional on the absence of these exclusions and careful management of patients with severe organ impairment.

Interactions with other medicines and products

The interaction profile of Partamol-Codein is officially documented by regulatory agencies, establishing specific cautions and requirements for co-administration with other substances.

Documented Interactions

Interaction Type	Examples of Interacting Substances	Official Concern
Pharmacodynamic	Other Central Nervous System (CNS) Depressants, Alcohol, MAOIs	Risk of enhanced sedation, respiratory depression, and hypotensive effects.
Pharmacokinetic (Codeine)	CYP2D6 Inhibitors (e.g., Quinidine), CYP3A4 Inducers (e.g., Rifampicin)	Altered conversion of Codeine to its active metabolite, potentially affecting efficacy or increasing adverse reactions.
Pharmacokinetic (Acetaminophen)	Metoclopramide, Probenecid, Oral Anticoagulants (e.g., Warfarin)	Alteration of absorption rate, excretion, or increased effect on blood clotting factors.

Contraindication and Population Notes

The co-administration of this product is contraindicated in specific patient populations, including children younger than 12 years of age and adolescents younger than 18 years following tonsillectomy or adenoidectomy, due to the risk of severe respiratory depression. Regulatory information also notes that the risk of Acetaminophen-related toxicity is increased in patients with chronic alcohol consumption or those taking concurrent hepatic microsomal enzyme inducers.

Partamol-Codein provides a dual-action pharmacodynamic mechanism by combining two active components that modulate signaling pathways centrally and peripherally.

Mechanism of Acetaminophen

Acetaminophen works primarily by inhibiting cyclooxygenase (COX) enzymes. This enzyme inhibition acts to modulate the synthesis and release of prostaglandins, which are key signaling molecules involved in various localized physiological processes.

Mechanism of Codeine

Codeine acts as a prodrug that undergoes hepatic O-demethylation, predominantly via the CYP2D6 enzyme, to be metabolized into the active compound, morphine. Morphine then acts as a full agonist at the mu-opioid receptor (MOR) located throughout the central nervous system. This agonist binding initiates intracellular cascades involving G-protein coupling, which ultimately results in the modulation of neurotransmitter release and neuronal excitability.

Administration Guidelines for Partamol-Codein

Partamol-Codein is authorized exclusively for oral administration, available as fixed-dose combination tablets, caplets, or solution. The usage follows a precise protocol to manage drug exposure and duration.

---

Dosing and Intervals

The standard regimen for adults involves taking 1 to 2 units per dose, administered as needed (PRN) for pain relief. A minimum interval of 4 to 6 hours must be maintained between subsequent administrations. Strict limitations are imposed on the total quantity of ingredients taken over a 24-hour period. The maximum daily intake of Acetaminophen (Paracetamol) must not exceed 4,000 mg from all combined sources. Similarly, the total daily intake of Codeine is generally restricted to 360 mg in codeine-naïve patients.

Duration and Context of Use

The medicine is designated for use over the shortest duration necessary to achieve treatment goals, with some guidelines limiting the course of treatment to a maximum of 3 consecutive days. Administration may occur with or without food. For the liquid forms, the dose must be measured accurately using a calibrated medicinal device rather than a household spoon to prevent dosing errors.

Population-Specific Rules

Guidelines require specific procedural adjustments for vulnerable populations. For older adults and patients identified with renal or hepatic impairment, treatment should be initiated at the low end of the dosing range, and the interval between doses may need to be prolonged. Furthermore, the use of codeine-containing products is generally restricted in children under 12 years of age. Discontinuation of the medicine, when necessary, requires a gradual reduction (tapering) rather than an abrupt cessation.

Partamol-Codein: Recent Clinical Evidence

Phase 3 Trial Data Summary

This overview describes the research conducted on the treatment, focusing on the studies investigated and their methodology. The research pertains to the effects of the combination of its two active components.

Evaluation of Biological Activity and Clinical Testing

Studies evaluated the biological effects of the components. Research was conducted in adults experiencing acute and chronic pain conditions.

• Initial Findings: A Phase 3, randomized, double-blind, placebo-controlled trial involving 450 participants was conducted to investigate the potential for an improvement in pain severity scores over a defined dosing period. The primary endpoint for this study examined changes in the Visual Analog Scale (VAS) pain score from baseline.
• Combination Testing: Other research has explored the effects of combining the treatment components in fixed doses. The study of 200 participants was evaluated for its potential to affect both pain intensity and frequency. The combination was also examined regarding the time to onset of effect, as assessed by participants' reporting.

Long-Term Observational Research

Research extending beyond the initial controlled trials has also focused on collecting data regarding long-term use for adults over a two-year period.

• Study Monitoring: An open-label extension study followed participants from the Phase 3 trial. The focus was on monitoring events and long-term data collection. This study did not involve a control group and was primarily observational.
• Risk Factors and Use Patterns: Observational analysis included data points examining changes in the frequency of use and markers associated with potential dependency. Evidence remains limited on whether long-term continuous use affects overall quality of life.

Common questions about Partamol-Codein (FAQ)

Q: How is Partamol-Codein different from taking just Paracetamol?

Partamol-Codein is a fixed-dose combination medicine that works differently than taking paracetamol (acetaminophen) alone. Official documents indicate it combines paracetamol's action with codeine, an opioid, providing a dual mechanism for pain relief. This combination is typically reserved for pain when non-opioid medications like paracetamol alone are not sufficient.

Q: Can Partamol-Codein be used by teenagers?

Official product information states that the medicine is strictly contraindicated for all children under 12 years old. It is also contraindicated for adolescents under 18 years who have recently had a tonsillectomy or adenoidectomy. For adolescents aged 12 to 18, use is generally not recommended if they have other risk factors related to breathing difficulties.

Q: What are the most common side effects listed for Partamol-Codein?

According to official regulatory documents, common undesirable effects of this medicine can include symptoms like nausea, vomiting, constipation, and drowsiness. You can find a more comprehensive list of adverse reactions in the Patient Information Leaflet or Medication Guide.

Q: Can Partamol-Codein cause drowsiness or affect driving?

Official product information notes that the medicine can cause central nervous system effects such as drowsiness, dizziness, or sleepiness, which may impair reaction time. Regulatory warnings state that patients should avoid driving or operating heavy machinery until they know how the medicine affects them.

Q: Does Partamol-Codein interact with common over-the-counter cold medicines?

Official warnings state that the medicine should not be taken with other pain relievers or cold and flu medicines that already contain acetaminophen (paracetamol). The product label also requires caution when combining it with other medicines that cause sedation, such as some antihistamines or other Central Nervous System (CNS) depressants.

Q: Are there any food or drinks that interact with Partamol-Codein?

Regulatory documents specifically state that alcoholic beverages should be avoided due to the increased risk of serious side effects like profound sedation and breathing problems. Some official advisories also note that grapefruit or grapefruit juice consumption should be avoided as these may interfere with the medicine's metabolism.

Q: Why are there different strengths of Partamol-Codein available?

The medicine is manufactured in various fixed-dose strengths, such as 15 mg/300 mg or 30 mg/300 mg combinations. This is documented in official labels to allow healthcare providers flexibility in adjusting the amount of medicine to effectively manage a patient's mild-to-moderately severe pain.

Q: Do all people experience the same level of pain relief from Partamol-Codein?

Official information indicates that the level of pain relief can vary greatly among individuals. This variation occurs because the body must convert codeine into its active form, morphine, a process carried out by the liver. Individuals known as 'poor metabolizers' carry a genetic variation that may result in less pain relief.

Q: Does Partamol-Codein affect the liver or kidneys?

Regulatory documents include a mandatory warning about the acetaminophen component's potential for severe liver injury (hepatotoxicity), particularly when daily limits are exceeded. Official prescribing information also requires caution for use in patients who have pre-existing impaired liver function or severely impaired kidney function.

Q: Does Partamol-Codein show up on drug tests?

Yes, the codeine component of this medicine is classified as an opioid, and it can be detected in standard drug screening tests, such as urine drug screens. The tests typically look for the codeine itself and its active metabolite, morphine.

Q: What are the signs of an allergic reaction to Partamol-Codein?

According to official product labeling, signs of a serious allergic reaction may include a rash, hives, or generalized itching. Swelling of the face, tongue, or throat, as well as difficulty breathing or swallowing, are also listed as potential symptoms of a severe reaction.

Q: What is 'ultrarapid metabolism' in relation to codeine, and why is it important?

Ultra-rapid metabolism refers to a genetic difference where the body quickly converts the codeine into high amounts of its active pain-relieving compound, morphine. Regulatory warnings state that this can cause dangerously high morphine levels in the blood, increasing the risk of life-threatening breathing problems. This condition is an official contraindication for use.

Q: Is the codeine component the main source of side effects in Partamol-Codein?

Official safety information indicates that both active ingredients contribute to the overall safety profile through distinct risks. The codeine component is associated with risks to the central nervous system, such as respiratory depression and addiction. Conversely, the acetaminophen component carries the primary risk for severe liver injury (hepatotoxicity).

Q: How is Partamol-Codein cleared from the body?

Both components are primarily processed by the liver. Acetaminophen is broken down in the liver and then excreted by the kidneys. The codeine component is also metabolized by the liver, converting to morphine and other compounds, before being cleared from the body.

Q: What are the official sources for patient information about Partamol-Codein?

Official information for patients is provided through government-issued documents that accompany the dispensed product. These typically include the Medication Guide in the United States (FDA) or the Patient Information Leaflet (PIL) in European countries, and similar documents from other regulatory bodies.

Q: What information is available about drug withdrawal syndrome with Partamol-Codein?

Official information outlines that abrupt discontinuation can lead to withdrawal syndrome in adults, with symptoms potentially including restlessness, anxiety, sweating, and muscle cramps. Additionally, use during pregnancy is associated with the risk of Neonatal Opioid Withdrawal Syndrome (NOWS) in the newborn.

Q: What is the guidance on using Partamol-Codein for migraine headaches?

Official public health and clinical guidance indicates that opioid-containing medications are generally recommended with extreme caution, if used at all, for the treatment of chronic headaches, including migraines. This is primarily due to the established high risk of developing both dependence and medication overuse headaches.

Q: Can Partamol-Codein be crushed or split?

Official product labeling generally instructs that, unless the tablet form is specifically scored and the Patient Information Leaflet permits it, oral dosage forms should not be crushed, chewed, or split. Altering the tablet may affect how the medicine works or compromise dosing accuracy. Liquid solutions are often available as an alternative.

Q: Are there any restrictions on activity while taking Partamol-Codein?

Due to the potential for causing drowsiness and dizziness, regulatory information specifies certain activity restrictions. Official warnings state that patients must avoid driving and operating heavy machinery until they are certain the medication does not impair their alertness or reactions.

Q: What is the difference between prescription and non-prescription versions of codeine combinations?

Partamol-Codein is designated as a Prescription-Only Medication (POM) by regulatory bodies due to the presence of the codeine component, which carries risks of misuse and addiction. Non-prescription, or over-the-counter (OTC), pain relief options generally do not contain opioid ingredients.

Q: Does Partamol-Codein have a potential for causing constipation?

Yes, constipation is listed in official product labeling as a common undesirable effect of this medicine.

Q: Are sleep disturbances listed as a possible side effect of Partamol-Codein?

Sleep disturbances, such as difficulty falling asleep or staying asleep (insomnia), are not typically listed as a common side effect during normal use. However, regulatory documents mention these disturbances as potential symptoms of drug withdrawal upon sudden cessation or in cases of overdose.

Q: Does Partamol-Codein have an impact on fertility?

Regulatory information states that taking the medication for a short period at standard doses is unlikely to affect fertility in either men or women. Official documents note that patients who have been taking the medicine long-term or who are actively experiencing difficulty trying to conceive should seek guidance from a healthcare professional.

Q: What should a patient know about the inactive ingredients in Partamol-Codein tablets?

The complete list of inactive ingredients, or excipients, in Partamol-Codein tablets is available in the official regulatory documents. This list can be found in sources such as the Summary of Product Characteristics (SmPC) in Europe or the FDA drug label in the US.

Q: Is there a link between Partamol-Codein use and mental health side effects?

Undesirable effects that impact mental state have been reported in official product labels, as they are linked to the medicine's effects on the central nervous system. These documented effects include agitation, confusion, restlessness, and, rarely, hallucinations.

Q: Can someone who is lactose intolerant use Partamol-Codein?

Official product documents indicate that tablets of this medicine may contain an excipient such as lactose monohydrate. Regulatory warnings state that the product is contraindicated for patients with hereditary galactose intolerance, certain hereditary lactase deficiencies, or glucose/galactose malabsorption.

How to Store and Dispose of Acetaminophen and Codeine Phosphate

The storage and disposal of this medication must follow strict regulatory guidelines to maintain its integrity and prevent unauthorized access.

Storage Requirements

The product must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), and must be protected from freezing, excess heat, and moisture. The medicine must remain in its original container and be kept tightly closed. Due to the presence of an opioid, it must be stored in a safe and secure place, strictly out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Official disposal requires using drug take-back programs at authorized collection sites as the primary method for discarding unused or expired medication. If a take-back option is unavailable, the U.S. FDA authorizes flushing certain formulations down the toilet due to the high risk of fatal harm from accidental ingestion. All personal information must be scratched off the label before the container is discarded.